Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Inclusion Criteria: * 1\. Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria (4 of 11 ACR criteria), * 2\. SLEDAI ≥4 and ≤10, * 3\. Positive Anti-nuclear Antibodies (ANA) and/or Positive anti-dsDNA antibodies * 4\. Male or female between 18 and 50 years of age * 5\. Current immunity to measles, mumps, rubella and varicella, as evidenced by positive IgG titers at the time of screening, * 6\. For subjects recruited during local influenza season, current vaccination against seasonal influenza at least 7 days prior to randomization, * 7\. Vaccination against H1N1 influenza at least 7 days prior to randomization. * 8\. For subjects with reproductive potential (males and females), use of a reliable means of contraception * 9\. Written informed consent obtained from the subject. Exclusion Criteria: * 1\. Any serious manifestation of lupus at entry, that, in the opinion of the investigator is likely to require initiation of off-protocol medication changes during the course of the study and in particular no BILAG A score, * 2\. Any non-SLE manifestation likely to require, in the investigator's judgment, treatment with high-dose corticosteroids or the addition of an immunosuppressive regimen during the course of the trial, * 3\. Received \> 20 mg/day of prednisone equivalent for \> 7 days during the 30 days prior to screening, * 4\. Currently receiving or having received pulse dose corticosteroids or intravenous immunoglobulin (IVIg) within 3 months prior to screening, * 5\. Received cyclophosphamide within 3 months prior to screening, * 6\. Received a monoclonal antibody during the 6 months prior to screening, * 7\. Previously received an investigational treatment directed against IFNa, * 8\. Received B-cell depleting therapy (e.g. Rituximab) within 12 months * 9\. Received IV antibiotics during the 30 days prior to screening, * 10\. Significant electrocardiogram (ECG) abnormalities , * 11\. Evidence of any clinically significant abnormality on a chest X-ray which, in the opinion of the investigator could represent active infection, latent tuberculosis or treatable manifestation of lupus, * 12\. Any laboratory abnormality that is clinically relevant * 13\. History of malignancy except completely excised basal cell carcinoma, * 14\. Congenital immune deficiency, * 15\. Positive IgM antibody titers in the presence of negative IgG titers to Epstein-Barr virus (EBV) or cytomegalovirus (CMV), * 16\. Frequent recurrences of oral or genital herpes simplex lesions (≥ 6 / year), * 17\. Episode of shingles within one year of screening, * 18\. Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV) or HBV (HBsAg, anti-HBc ab) positive, * 19\. Any current signs or symptoms of infection at entry, * 20\. Administration of any live vaccine within the 3 months prior to study entry * 21\. Planned use of any investigational or non-registered product